BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38435427)

  • 1. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
    Velasco-Hernandez T; Trincado JL; Vinyoles M; Closa A; Martínez-Moreno A; Gutiérrez-Agüera F; Molina O; Rodríguez-Cortez VC; Ximeno-Parpal P; Fernández-Fuentes N; Petazzi P; Beneyto-Calabuig S; Velten L; Romecin P; Casquero R; Abollo-Jiménez F; de la Guardia RD; Lorden P; Bataller A; Lapillonne H; Stam RW; Vives S; Torrebadell M; Fuster JL; Bueno C; Sarry JE; Eyras E; Heyn H; Menéndez P
    Hemasphere; 2024 Feb; 8(2):e45. PubMed ID: 38435427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hif-1α Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML.
    Velasco-Hernandez T; Soneji S; Hidalgo I; Erlandsson E; Cammenga J; Bryder D
    Stem Cell Reports; 2019 Jan; 12(1):112-121. PubMed ID: 30595549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxic exposure activates the B cell-specific Moloney murine leukaemia virus integration site 1/PI3K/Akt axis and promotes EMT in leukaemia stem cells.
    Jiang M; He G; Li J; Li J; Guo X; Gao J
    Oncol Lett; 2021 Feb; 21(2):98. PubMed ID: 33376531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting.
    Chen Y; Li J; Xu L; Găman MA; Zou Z
    Cell Death Discov; 2022 Sep; 8(1):397. PubMed ID: 36163119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.
    Herbrich S; Baran N; Cai T; Weng C; Aitken MJL; Post SM; Henderson J; Shi C; Richard-Carpentier G; Sauvageau G; Baggerly K; Al-Atrash G; Davis RE; Daver N; Zha D; Konopleva M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
    Martiáñez Canales T; de Leeuw DC; Vermue E; Ossenkoppele GJ; Smit L
    Cancers (Basel); 2017 Jun; 9(7):. PubMed ID: 28665351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
    Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
    Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
    Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.
    Barbosa K; Deshpande AJ
    Front Oncol; 2023; 13():1204895. PubMed ID: 37601659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
    Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
    Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy.
    Kikushige Y
    Blood Cell Ther; 2022 Dec; 5(Spec Edition):S1-S5. PubMed ID: 37220607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia induces inflammatory microenvironment by priming specific macrophage polarization and modifies LSC behaviour via VEGF-HIF1α signalling.
    Jiang M; He G; Wang J; Guo X; Zhao Z; Gao J
    Transl Pediatr; 2021 Jul; 10(7):1792-1804. PubMed ID: 34430427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
    Hansen Q; Bachas C; Smit L; Cloos J
    Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.
    Niu J; Peng D; Liu L
    Front Oncol; 2022; 12():896426. PubMed ID: 35865470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting acute myeloid leukemia stem cell signaling by natural products.
    Siveen KS; Uddin S; Mohammad RM
    Mol Cancer; 2017 Jan; 16(1):13. PubMed ID: 28137265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence.
    O'Reilly E; Zeinabad HA; Nolan C; Sefy J; Williams T; Tarunina M; Hernandez D; Choo Y; Szegezdi E
    Front Cell Dev Biol; 2021; 9():662868. PubMed ID: 34589478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches.
    Hira VVV; Van Noorden CJF; Carraway HE; Maciejewski JP; Molenaar RJ
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):183-198. PubMed ID: 28363872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.